Viking Therapeutics Quarterly Balance Sheet
NASDAQ: VKTXHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viking Therapeutics financial position
As of Jun 30, 2026, Viking Therapeutics reported total assets of $521.9 million, down 37.0% from a year earlier against total liabilities of $113.6 million. Shareholders' equity stood at $408.3 million, or 78.2% of assets. The company held $125.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.72, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Viking Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 125.75M | 118.12M | 165.81M | 100.38M | 33.88M | 37.94M | 26.68M | 50.35M | 43.91M | 195.58M | 55.52M | 37.19M |
| Short-Term Investments | 375.91M | 484.85M | 539.93M | 614.19M | 773.84M | 813.92M | 875.94M | 880.09M | 898.35M | 767.40M | 306.56M | 339.06M |
| Total Current Assets | 517.56M | 608.21M | 715.60M | 738.70M | 827.02M | 866.02M | 907.22M | 936.65M | 945.72M | 966.34M | 367.23M | 381.30M |
| Total Assets | 521.90M | 608.24M | 715.73M | 739.41M | 827.85M | 866.99M | 908.32M | 937.89M | 946.84M | 967.52M | 368.49M | 382.66M |
| Accounts Payable | 69.01M | 67.18M | 53.25M | 4.41M | 5.49M | 7.70M | 9.81M | 254.00K | 11.09M | 5.22M | 7.51M | 5.71M |
| Total Current Liabilities | 109.66M | 106.33M | 76.67M | 26.07M | 31.98M | 19.57M | 27.41M | 25.68M | 25.09M | 32.77M | 19.14M | 13.40M |
| Total Liabilities | 113.58M | 106.33M | 76.67M | 26.39M | 32.39M | 20.07M | 28.04M | 26.44M | 25.86M | 33.63M | 20.07M | 14.42M |
| Shareholders' Equity | 408.32M | 501.92M | 639.06M | 713.03M | 795.46M | 846.92M | 880.28M | 911.45M | 920.98M | 933.89M | 348.42M | 368.24M |
| Retained Earnings | -1.13B | -1.01B | -847.55M | -689.88M | -599.10M | -533.54M | -487.91M | -452.49M | -427.55M | -405.30M | -377.94M | -353.34M |
| Net Cash (Debt) | 501.66M | 602.96M | 705.74M | 714.57M | 807.72M | 851.86M | 902.61M | 930.44M | 942.26M | 962.98M | 362.08M | 376.24M |
| Shares Outstanding | 116.65M | 115.89M | 114.79M | 112.45M | 112.33M | 112.29M | 111.57M | 111.43M | 110.80M | 110.23M | 100.11M | 100.03M |
This table shows 12 quarterly periods of Viking Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 11 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow VKTX's reporting calendar. What is a balance sheet?